Stifel Nicolaus Lowers Kura Oncology (NASDAQ:KURA) to Hold

Stifel Nicolaus lowered shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a hold rating in a report published on Monday morning, Marketbeat reports. They currently have $19.00 target price on the stock, down from their prior target price of $26.00.

Several other equities research analysts also recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. JMP Securities reissued a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Wedbush reissued an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus target price of $29.20.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA opened at $18.27 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. The firm has a market cap of $1.39 billion, a PE ratio of -8.42 and a beta of 0.84. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17. The business has a fifty day moving average of $19.56 and a 200-day moving average of $20.25.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the company posted ($0.53) earnings per share. On average, equities research analysts predict that Kura Oncology will post -2.45 EPS for the current fiscal year.

Institutional Trading of Kura Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in KURA. Susquehanna Fundamental Investments LLC bought a new position in Kura Oncology in the first quarter valued at $507,000. Hennion & Walsh Asset Management Inc. increased its position in shares of Kura Oncology by 42.3% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 181,674 shares of the company’s stock valued at $3,875,000 after acquiring an additional 54,031 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after acquiring an additional 577,732 shares in the last quarter. Vanguard Group Inc. boosted its position in Kura Oncology by 0.7% during the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock valued at $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Finally, Sofinnova Investments Inc. grew its stake in Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after purchasing an additional 323,303 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.